The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback